Learn About Follicular Lymphoma

What is the definition of Follicular Lymphoma?
Follicular lymphoma is a type of slow-growing non-Hodgkin lymphoma (NHL), which is a cancer that affects the lymphatic system. The lymphatic system is part of the immune system and consists of lymph vessels, lymph fluid, lymph nodes, bone marrow, the spleen, and lymphocytes. The two main types of lymphocytes are B-lymphocytes (B-cells), which produce antibodies to fight off infection, and T-lymphocytes (T-cells), which can destroy invading microorganisms or cancer cells. Follicular lymphoma is a cancer of the B-cells, in which the B-cells tend to form follicles (clusters) in the lymph nodes. As the cancerous B-cells spread, they cause lymph nodes to swell. Follicular lymphoma is categorized in stages I-V, depending on its severity and how many lymph nodes and other areas are affected. There are 3 types of follicular lymphoma: 1) transformed follicular lymphoma, in which the slow-growing cancer transforms into an aggressive diffuse B-cell lymphoma (DLBCL); 2) primary gastrointestinal follicular lymphoma, in which the cancer affects the small intestines; and 3) pediatric follicular lymphoma, in which the cancer is different in children than adults, remains in the area it first developed, and tends to be more benign.
Save information for later
Sign Up
What are the symptoms of Follicular Lymphoma?
In some individuals, follicular lymphoma may not cause any symptoms. Symptoms of follicular lymphoma may include persistent fatigue; fever; night sweats; unexplained weight loss; hard, painless, and swollen lymph nodes in neck, armpits, or groin; abdominal pain or swelling; enlarged spleen; chest pain; coughing; lightheadedness; headaches; paleness; bruising or bleeding easily; low levels of red blood cells, white blood cells, and platelets (cytopenia); anemia; and difficulty breathing. Symptoms of follicular lymphoma tends to come and go as relapses and remissions.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Follicular Lymphoma?
Treatment for follicular lymphoma depends on the stage of the disease and may require a multidisciplinary team of doctors and other specialists. Treatment for follicular lymphoma may include watching and waiting (for individuals with no symptoms), radiation therapy, immunotherapy, and chemotherapy. Individuals with advanced follicular lymphoma may be treated with anti-CD20 monoclonal antibody medications, such as rituximab (Rituxan) and obinutuzumab (Gazyva); chemotherapy regimens, such as bendamustine plus rituximab and CHOP-R (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone given along with rituximab); or rituximab with chlorambucil (Leukeran) or lenalidomide (Revlimid). Some individuals with follicular lymphoma may require maintenance therapy or medications for relapsed or refractory (resistant) lymphoma, such as idelalisib (Zydelig) or copanlisib (Zydelig), radioimmunotherapy combined with Ibritumomab tiuxetan (Zevalin), or Ibritumomab tiuxetan.
Who are the top Follicular Lymphoma Local Doctors?
SN
Dr. Sattva S. Neelapu
Oncology | Hematology Oncology
Elite
Highly rated in
24
conditions
Oncology
Hematology Oncology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Sattva Neelapu is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Neelapu has been practicing medicine for over 31 years and is rated as an Elite doctor by MediFind in the treatment of Follicular Lymphoma. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Non-Hodgkin Lymphoma. He is licensed to treat patients in Texas. Dr. Neelapu is currently accepting new patients.

View Profile
FS
Dr. Felipe Samaniego
Oncology
Elite
Highly rated in
21
conditions
Oncology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Felipe Samaniego is an Oncologist in Houston, Texas. Dr. Samaniego has been practicing medicine for over 39 years and is rated as an Elite doctor by MediFind in the treatment of Follicular Lymphoma. He is also highly rated in 21 other conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, and B-Cell Lymphoma. He is licensed to treat patients in Texas. Dr. Samaniego is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
AY
Dr. Anas M. Younes
Oncology
Elite
Highly rated in
25
conditions
Oncology

RWJBarnabas Health

1275 York Ave 
New York, NY 10065

Anas Younes is an Oncologist in New York, New York. Dr. Younes has been practicing medicine for over 39 years and is rated as an Elite doctor by MediFind in the treatment of Follicular Lymphoma. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma. He is licensed to treat patients in New York and Texas.

View Profile
View All Doctors
What are the latest Follicular Lymphoma Clinical Trials?
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
Who is this study for: Patients with Follicular Non-Hodgkin Lymphoma
Status: Active, not recruiting
Start Date: July 2012
Intervention Type: Drug
Study Drugs: Ibritumomab Tiuxetan, Bendamustine, Intensol, Doxorubicin, Rituximab
Phase: Phase 3
View Trial
Summary: Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed b...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse
Who is this study for: Patients with Follicular Lymphoma
Status: Recruiting
Start Date: October 2007
Intervention Type: Biological
Phase: Phase 2
View Trial
Summary: Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve second (first, in the case of patients who have never achieved complete response following standard first-line treatment) complete response through autologous stem cell transp...
View All Clinical Trials
What are the Latest Advances for Follicular Lymphoma?
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Condition: B-Cell Non-Hodgkin's Lymphoma (NHL)
Journal: JCO global oncology
Treatment Used: 1L Rituximab-CHOP (R-CHOP)
Published: April 29, 2022
View publication
Summary: Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Condition: B-cell Non-Hodgkin Lymphoma
Journal: The Lancet. Haematology
Treatment Used: Odronextamab
Number of Patients: 145
Published: April 03, 2022
View publication
Summary: Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Tired of the same old research?
Check Latest Advances
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Condition: Relapsed or Refractory Follicular Lymphoma
Journal: The Lancet. Haematology
Treatment Used: Three or More Lines of Systemic Therapy
Number of Patients: 933
Published: March 31, 2022
View publication
Summary: Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
View All Latest Advances